NCT03204188
Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma treatment 2 active_not_recruiting NCT01370772
Intensified Rituimab Prephase Before FCR in Untreated B-CLL treatment 2 completed NCT00328198
Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia treatment 2 completed NCT01612988
Treatment With Bendamustine, Ofatumumab and MethylPrednisolone in Relapsed B-CLL No drug interventions treatment 2 terminated NCT03331198
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) treatment 1 / 2 recruiting NCT05947851
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010) treatment 3 recruiting NCT03462719
A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) treatment 3 active_not_recruiting NCT03900598
A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 1 active_not_recruiting NCT04210219
A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia No drug interventions treatment 1 active_not_recruiting NCT04540796
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 1 active_not_recruiting NCT04876092
A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL treatment 1 active_not_recruiting NCT05424822
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 1 recruiting NCT05963074
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia treatment 2 recruiting NCT06299540
Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia Not Available Not Available recruiting NCT02298816
B-Cell Hematologic Malignancy Vaccination Registry No drug interventions Not Available Not Available withdrawn NCT05024045
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers treatment 1 active_not_recruiting NCT05797233
Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies treatment 1 active_not_recruiting NCT05094206
CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies No drug interventions treatment 1 terminated NCT06364423
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL) treatment 1 / 2 recruiting NCT01126502
Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia treatment 1 terminated NCT01005979
A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL) treatment 1 terminated NCT02782351
Humanized CAR-T Therapy for Treatment of B Cell Malignancy No drug interventions treatment 1 / 2 unknown_status NCT01105247
Safety of PCI-32765 in Chronic Lymphocytic Leukemia treatment 1 / 2 completed NCT00774345
A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy treatment 3 completed NCT01258998
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma No drug interventions treatment 2 completed NCT00101205
Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma treatment 1 terminated NCT00927797
Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL) treatment 2 unknown_status NCT00302861
A Study to Evaluate the Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) No drug interventions Not Available 1 / 2 terminated NCT03720561
A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting Not Available Not Available completed NCT03343678
This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax treatment 1 withdrawn NCT01576588
Rituximab in Pretreated Elderly or Unfit B-CLL Patients treatment 2 completed NCT03301207
A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy other 1 completed NCT00771056
Hydroxychloroquine in Untreated B-CLL Patients treatment 2 terminated NCT01400685
Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL treatment 1 completed NCT02440685
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors treatment 1 / 2 terminated NCT03757000
A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies No drug interventions treatment 1 unknown_status NCT04271800
Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma No drug interventions treatment 1 / 2 recruiting NCT01982175
Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia treatment 2 suspended NCT05244070
A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma treatment 1 terminated NCT00098670
Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia treatment 2 completed NCT02454270
A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies treatment 1 terminated NCT02685670
Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma treatment 1 / 2 unknown_status NCT02406742
A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma treatment 1 / 2 completed NCT02733042
A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia treatment 1 / 2 completed NCT00005799
Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer treatment Not Available completed NCT00336206
Low Dose Alemtuzumab for Consolidation and Maintenance of Patients With B-Cell Chronic Lymphocytic Leukemia treatment Not Available unknown_status NCT05515406
A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL No drug interventions treatment 1 recruiting NCT02213913
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas treatment 1 / 2 active_not_recruiting NCT05259813
Phase I Study of JWCAR029 in Subjects With R/R CLL/SLL No drug interventions treatment 1 withdrawn NCT01158118
Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors treatment 2 completed NCT02437019
Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Not Available Not Available approved_for_marketing NCT03265717
DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic Leukemia treatment 2 terminated NCT04849416
A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) treatment 2 active_not_recruiting NCT02759016
Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib treatment 1 completed NCT00626496
Family Study of Lymphoproliferative Disorders No drug interventions Not Available Not Available recruiting NCT01292135
Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL) treatment 1 completed NCT00058786
Treatment of Chronic Lymphocytic B-Leukemia With IL-2 and CD-40 Autologous Tumor Cells No drug interventions treatment 1 completed NCT02757586
Treatment of Chronic Lymphocytic Leukemia No drug interventions Not Available Not Available unknown_status NCT00344786
Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL treatment 1 terminated NCT00648739
Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM treatment 1 / 2 terminated NCT00768339
A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas treatment 1 / 2 terminated NCT02336048
A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities treatment 1 terminated NCT00951457
Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL) treatment 1 / 2 completed NCT03151057
Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies treatment 1 terminated NCT01744626
Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma treatment 1 completed NCT00006226
Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia treatment 2 completed NCT00003620
Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia treatment 2 completed NCT03289182
An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) Not Available Not Available completed NCT01110473
ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies treatment 1 completed NCT00058227
Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma treatment 1 completed NCT03502876
Tolerance and Resistance to Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL No drug interventions Not Available Not Available completed NCT00089076
MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma treatment 1 / 2 terminated NCT01144260
Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) treatment 2 completed NCT01649791
Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia treatment Not Available terminated NCT01212380
Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL) treatment 1 completed NCT00086580
Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients treatment 3 completed NCT01373229
Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL) treatment 1 completed NCT01864889
Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19 No drug interventions treatment Not Available unknown_status NCT03746392
Project to Improve Communication About Serious Illness - Pilot Study No drug interventions supportive_care Not Available completed NCT00058240
Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma treatment 1 / 2 completed NCT03110640
Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma treatment 1 unknown_status NCT01735604
Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy No drug interventions treatment 1 / 2 unknown_status NCT00377104
Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma treatment 1 terminated NCT02361346
Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL No drug interventions treatment 1 / 2 terminated NCT02743546
Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma treatment 1 withdrawn NCT00697346
Study of MLN8237 in Participants With Advanced Hematological Malignancies treatment 1 completed NCT00398112
Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma treatment 2 completed NCT00290810
Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia treatment 2 completed NCT00861510
A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies treatment 1 completed NCT00565981
A Pilot Trial With Subcutaneous Alemtuzumab and Oral Fludarabinephosphate for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of Response treatment 2 completed NCT04160195
T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma treatment 1 terminated NCT04030195
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL treatment 1 / 2 completed NCT00545714
A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL) treatment 2 completed NCT03476655
Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India Not Available Not Available completed NCT00918450
Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing Regimen treatment 2 withdrawn NCT00800943
Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After Chemotherapy treatment 2 unknown_status NCT06205290
A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies treatment 3 withdrawn NCT00201721
Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia treatment 2 completed NCT02846584
a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies No drug interventions treatment 2 unknown_status NCT00435084
A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the Treatment of Refractory B-CLL treatment 1 / 2 completed NCT02912754
Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients treatment 1 / 2 unknown_status NCT00224354
Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cells treatment 1 withdrawn NCT03755947
Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia treatment 2 completed NCT02666898
Phase II Trial GA101 Inbrutinib B CLL treatment 2 completed NCT00046683
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia treatment 3 completed NCT01732861
Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma treatment 1 completed NCT00220311
A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia treatment 4 completed NCT00098371
Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia treatment 2 terminated NCT03088878
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies treatment 1 / 2 active_not_recruiting NCT00098488
17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia treatment 1 terminated NCT02168907
CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma treatment 1 terminated NCT05645107
A Study to Evaluate Efficacy, Safety, and Pharmacokinetics of XEMBIFY® Plus Standard Medical Treatment (SMT) Compared to Placebo Plus SMT to Prevent Infections in Participants With Hypogammaglobulinemia and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia treatment 3 recruiting NCT02037256
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma treatment Not Available completed NCT01269385
Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia treatment 1 / 2 completed NCT01296932
BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL) treatment 1 completed NCT00621452
Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma treatment 1 completed NCT05172700
Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer Not Available Not Available available NCT03097770
Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 No drug interventions treatment 1 / 2 completed NCT01217749
Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL treatment 1 / 2 completed NCT02315118
Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies treatment 1 / 2 unknown_status NCT00321724
AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia treatment 2 completed NCT00254163
Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients treatment 3 completed NCT00871663
Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6) treatment 1 completed NCT03685786
CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT treatment 1 unknown_status NCT03190330
A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion other 4 completed NCT04204057
Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) treatment 2 completed NCT00206726
Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL) treatment 2 completed NCT00485966
Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia treatment 2 withdrawn NCT01029366
CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy treatment 1 completed NCT00646165
Trial of Forodesine in Patients With Relapsed B-cell Chronic Lymphocytic Leukemia treatment 1 terminated NCT01456182
Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic Leukemia No drug interventions Not Available 1 withdrawn NCT00923182
A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia treatment 1 completed NCT01604031
Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide treatment 1 terminated NCT03425591
A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice Not Available Not Available completed NCT02381080
Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy treatment 1 completed NCT02869529
Institut Paoli Calmettes Chronic Lymphatic Leukemia Database No drug interventions Not Available Not Available recruiting NCT00738829
Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL treatment 1 / 2 completed NCT02842229
A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic Neoplasms No drug interventions Not Available Not Available completed NCT00867529
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma treatment 2 completed NCT00119392
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma treatment 2 completed NCT02757040
Combination of Ibrutinib and As2O3 in the Treatment of CLL treatment 3 unknown_status NCT00288067
Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma treatment 1 / 2 terminated NCT00147901
Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL) treatment 2 completed NCT05888701
"Don't Eat me" Signal in Hematological Malignancies: CD24 as New Target to Improve Anti-cancer Immunity. No drug interventions Not Available Not Available recruiting NCT00845104
Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment treatment 2 withdrawn NCT00290472
CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia treatment 2 completed NCT01109069
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia treatment 2 completed NCT02556346
Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma No drug interventions treatment 1 withdrawn NCT00871546
SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715) treatment 2 terminated NCT00612612
Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia treatment 1 terminated NCT00910910
Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial) treatment 3 completed NCT04271410
CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma No drug interventions treatment 1 / 2 recruiting NCT02639910
Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi treatment 2 completed NCT00558181
High-dose Methylprednisolone and Rituximab in High Risk B-CLL treatment 2 completed NCT01789255
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies supportive_care 2 completed NCT04290923
Determination of Blood Tumor Cells No drug interventions Not Available Not Available completed NCT05650723
Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab treatment 2 recruiting NCT03420183
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies treatment 1 / 2 recruiting